Summary.-Intrapleural growth of transplanted rat tumours was prevented or retarded by intrapleural administration of double-stranded RNA. A similar suppression of growth was achieved with peritoneal tumours by the intraperitoneal injection of the compound. These studies indicate the possible potential of this form of treatment of thoracic and peritoneal tumours for clinical application in the treatment of mesothelioma.
Summary.-Intrapleural growth of transplanted rat tumours was prevented or retarded by intrapleural administration of double-stranded RNA. A similar suppression of growth was achieved with peritoneal tumours by the intraperitoneal injection of the compound. These studies indicate the possible potential of this form of treatment of thoracic and peritoneal tumours for clinical application in the treatment of mesothelioma.
DIRECT contact between microbial adjuvants and tumour cells may often produce a more marked suppression of tumour growth than that achieved by general immunostimulation following their systemic administration. For example, with Corynebacterium parvum, growth of carcinomata in the mouse (Likhite and Halpern, 1973) and rat sarcomata (Pimm and Hopper, 1 975a) is restricted when cells are injected in admixture with killed organisms, and intralesional injections may lead to regression of a transplanted hamster melanoma (Paslin, Dimitrov and Heaton, 1974) . In addition, growth of syngeneically transplanted rat (Baldwin and Pimm, 1971) and mouse (Bartlett, Zbar and Rapp, 1972) sarcomata is suppressed when tumour cells are injected in admixture with Bacillus Calmette-C(terin (BCG) organisms. BCG contact with tumour cells similarly suppresses growth of other tumours, including rat and guinea-pig hepatomata (Zbar, Bernstein and Rapp, 1971; Hopper, Pimm and Baldwin, 1975a) , and a mammary carcinoma and epithelioma in the rat (Hopper et al., 1 975a; Baldwin and Pimm. 1973a) .
In addition to bacterial preparations, douible stranded RNA (ds-RNA) of viral origin is also tumour suppressive when injected subcutaneously in admixture with transplanted rat tumours. Thus, growth of rat sarcomata, a hepatoma, a mammary carcinoma and an epithelioma is prevented or retarded when cells are injected subcutaneously together with ds-RNA (Pimm, Embleton and Baldwin, 1975) and intralesional injections may restrict growth of subcutaneous transplants of mouse sarcomata and lymphomata (Heyes, Catherall and Harnden, 1974; Parr, Wheeler and Alexander, 1973 (Baldwin and Pimm, 1973b) and pulmonary metastases Pimm, 1973a, 1974) may be restricted by the introduction of BCG organisms into lung tissue by intravenous injection, and growth of intrapleural and intraperitoneal tumour is controlled by injection of BC'G inito these body cavities . More defined preparations, free of these side-effects known to be produced by mycobacterial materials (Pinsky et al., 1973; Hunt et al., 1973) are clearly desirable for clinical application of this treatment. Sin-ce intrapleurally or intraperitoneally injected BCG will suppress tumours at these sites , and ds-RNA injected locally Will suppress subcutaneous tumours , the studies to be described here were carried out to assess the influence of intrapleurally and intraperitoneally inijected ds-RNA on tumours at these sites. (Pimm and Baldwini, 1975) .
MATERIALS AND METHODS
Tumon,urs.-Tumours were induced with chemical carcinogens or arose without deliberatre induction in rats of an inbred Wistar strain and have been described previously . Single cell suspensions were prepared as previously described . Double stranded RNA (ds-RNA).-Fungal virus ds-RNA (BRL 5907) was supplied by
Beecham Research Laboratories, Betchworth, Surrey and prepared for injection as described previously . Transplantation of tumours. Pleural and peritoneal tumour growths wNere produced by injections of single cell suspensions as described previously 25, 29, 32, 32, 47 Terminated Day 30 14, 14, 14, 14, 14 Terminated Day 45 20, 20, 20, 20 34, 34, 35, 35, 35 21, 21, 25, 25, 25 34, 34, 34, 48, 49 27, 27, 27, 27 23, 23, 23, 27, 27 23, 23, 23, 27, 27 20, 20, 20, 20, 20 20, 20, 20, 20, 20 in Admixture tests with sarcoma Sp24 where progressive tumours were observed in all treated rats but in 2 of the 3 tests there was a significant increase in survival.
Treatment of intraperitoneal tumours
Further tests were carried out to assess the response to tumour cells injected intraperitoneally in admixture with ds-RNA and the results are compatible with those obtained employing intrapleural tumour challenge (Table III) . Thus, with both sarcoma Mc7 and Mc57 growth from a challenge inoculum of 2 x 106 tumour cells was totally suppressed by the presence of ds-RNA (250 ,ug). In comparison, challenges with sarcoma Sp24 (2-5 x 104 cells) and mammary carcinoma AAF57 (1 x 104 cells) were not suppressed when tumour cells were injected in admixture with ds-RNA although treatment did result in a significant increase in survival of sarcoma Sp24 treated rats.
DISCUSSION
It has previously been reported that the growth of subcutaneously transplanted rat tumours can be prevented or retarded by injecting tumour cells in admixture with ds-RNA . The present studies extend these observations, demonstrating that introduction of ds-RNA into the pleural and peritoneal cavities may control tumour growth at these sites and are comparable with earlier studies indicating that growth of these tumours can be controlled also by contacting them with BCG Baldwin and Pimm, 1971; Hopper et al., 1975a) . Here, too, growth of subcutaneous inocula of Mc induced sarcomata, mammary carcinoma AAF57 and sarcoma Sp24 can be prevented by admixture with BCG but efficient suppression of intrapleural and intraperitoneal growths is achieved only with the chemically induced sarcomata. There are differences in the responses to these 2 reagents, however, since whilst both ds-RNA and BCG exhibited a degree of inhibitory reactivity when given several days after tumour challenge, only BCG was effective prophylactically when given before the tumour cells.
The ds-RNA preparations used in the present studies are cytotoxic in vitro for rat tumour cells and this toxic response must contribute to some extent in the suppression of tumour growth at intraperitoneal and intrapleural sites. The finding that tumours vary quite markedly in their in vivo response to ds-RNA, this being correlated to some extent with the known immunogenicity of susceptible tumours suggests, however, that host responses are also involved. In this context it is relevant that the susceptibility of tumours to suppression in vivo by contact with ds-RNA closely approximates to their responses to BCG mediated suppression and in this case there is good evidence for an involvement of macrophages. This is emphasized by tests showing that macrophage depletion of rats by silica treatment abrogates BCG mediated suppression of tumour growth, although immunosuppression by whole body irradiation has no effect on this response Pimm and Hopper, 1975b) . Similar tests with ds-RNA are in progress in order to evaluate the role of host factors in its tumour suppressive action.
Whatever is the mode of action of ds-RNA, the present studies as well as the previous findings on the treatment of subcutaneous tumours (Pimm et al., 1.975) indicate that tumour suppression by locally administered agents is not restricted to bacterial adjuvants such as Corynebacteria and Mycobacteria, but can be achieved with more simple, water soluble agents. The double stranded RNA (BRL 5907) used throughout these studies is of natural viral origin but synthetic polynucleotides such as polyinosinic-polycytidylic acid (poly I-C) warrant investigation. Furthermore, in considering clinical application of these reagents, the toxicity of ds-RNA needs to be compared with that of bacterial adjuvants such as BCG. In this context, chemical modification of ds-RNA to reduce toxicity and increase tumour inhibitory activity is more feasible than with bacterial adjuvants where the active factor is ill defined. For example, Heyes et al. (1974) have reported that a polyquaternary ammonium complex of ds-RNA is more effective than the parent compound in suppressing growth of a mouse lymphoma. This compound is now being tested against the tumours described in this paper and, in addition, the feasibility of using ds-RNA compounds for the treatment of tumours at other anatomical sites, including pulmonary metastases, is being explored.
